+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma



Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma



Gynecologic Oncology 95(3): 762-764



Background. Primary treatment of endometrial cancer with progestogens is reserved for adjuvant or palliative treatment, although with unproven efficacy. Case. We present a case of early endometrial cancer where a combination of oral progestogens and levonorgestrel releasing intrauterine system (Mirena@) was used as a primary treatment, as the standard surgical treatment was deemed to carry an unacceptable mortality risk. Conclusion.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 012262805

Download citation: RISBibTeXText

PMID: 15582001

DOI: 10.1016/j.ygyno.2004.09.010


Related references

Levonorgestrel-releasing intrauterine system (Mirena ) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Gonadotropin-Releasing Hormone Agonist Combined With a Levonorgestrel-Releasing Intrauterine System or Letrozole for Fertility-Preserving Treatment of Endometrial Carcinoma and Complex Atypical Hyperplasia in Young Women. International Journal of Gynecological Cancer 27(6): 1178-1182, 2017

Serum levonorgestrel levels and endometrial thickness during extended use of the levonorgestrel-releasing intrauterine system. Contraception 80(1): 84-89, 2009

The levonorgestrel-releasing intrauterine system for endometrial protection during estrogen replacement therapy: a clinical review. Climacteric 18(4): 470-482, 2016

Endometrial safety with a low-dose intrauterine levonorgestrel-releasing system after 3 years of estrogen substitution therapy. Maturitas 48(1): 65-70, 2004

Levonorgestrel-releasing intrauterine system (Mirena) in compare to medroxyprogesterone acetate as a therapy for endometrial hyperplasia. Journal of Research in Medical Sciences 19(8): 686-690, 2014

Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstetrics and Gynecology 111(2 Pt 2): 547-549, 2008

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Endometrial Synovial-like Metaplasia Associated With Levonorgestrel-releasing Intrauterine System. International Journal of Gynecological Pathology 34(6): 570-575, 2016

Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database of Systematic Reviews 2013(6): Cd009458, 2013

Levonorgestrel-releasing intrauterine system vs. endometrial thermal ablation for menorrhagia. Hormones 8(1): 60-64, 2009

Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstetrical and Gynecological Survey 67(11): 726-733, 2013

Endometrial adenocarcinoma in association with a levonorgestrel-releasing intrauterine system (Mirena). Journal of Family Planning and Reproductive Health Care 32(2): 113-114, 2006

Levonorgestrel-Releasing Intrauterine System vs. Oral Progestins for Treatment of Endometrial Hyperplasia. American Family Physician 93(11): 948-949, 2017